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Putting the treatment of paediatric
schistosomiasis into context
Takafira Mduluza1,2* and Francisca Mutapi3
Abstract
Despite increased international efforts to control schistosomiasis using preventive chemotherapy, several challenges
still exist in reaching the target populations. Until recently, preschool-aged children had been excluded from the
recommended target population for mass drug administration, i.e. primary school children aged 6–15 years. Our
studies and those of others provided the evidence base for the need to treat preschool-aged children that led to
recommendations by the World Health Organization to include preschool-aged children in treatment programmes
in 2010. The major challenge now lies in the unavailability of a child-size formulation of the appropriate
anthelmintic drug, praziquantel.
The currently available formulation of praziquantel presents several problems. First, it is a large tablet, making it
difficult for young children and infants to swallow it and thus requires its breaking/crushing to allow for safe
uptake. Second, it is bitter so it is often mixed with a sweetener to make it palatable for young children. Third, the
current formulation of 600 mg does not allow for flexible dose adjustments for this age group. Thus, there is a
need to formulate a child-appropriate praziquantel tablet.
This paper discusses the target product profile for paediatric praziquantel, as well as knowledge gaps pertinent to
the successful control of schistosome infection and disease in preschool-aged children.
Keywords: Paediatric schistosomiasis, Praziquantel, Child-size medicine, Target product profile, Drug pipeline
Multilingual abstracts
Please see Additional file 1 for translation of the abstract
into the six official working languages of the United
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Background
Schistosomiasis or bilharzia is a water-borne parasitic in-
fection that results in a debilitating chronic disease with
extensive morbidity and organ pathology [1–3]. It is en-
demic in 76 countries worldwide, with about 207 million
people infected of which 123 million are children. The
majority (88%) of the people infected with schistosomia-
sis live on the African continent [2, 3].
There are two major types of schistosomiasis disease
manifestations: urogenital schistosomiasis (most preva-
lent in Africa) caused by Schistosoma haematobium, and
intestinal schistosomiasis, caused by, depending on the
tropical region of the world, either S. intercalatum, S.
mansoni, S. japonicum, S. guineensis or S. mekongi [4–6].
Schistosomiasis is implicated in several clinical condi-
tions including bladder cancer leading to death, liver cir-
rhosis, hydronephrosis, reproductive complications [7],
and human immunodeficiency virus (HIV) transmission
and fast progression to acquired immune deficiency syn-
drome (AIDS) in adults [8]. In children, it is associated
with poor growth, malnutrition, poor cognitive develop-
ment, iron-deficiency anaemia and reduced school per-
formance in the high-risk age group (5–15 years) [5, 6].
Encouragingly, several countries in Africa have now
embarked on national schistosome control programmes
utilising mass drug administration (MDA). The mass
treatments are targeting primary school-aged children fol-
lowing treatment regimens recommended by the World
Health Organization (WHO) [8]. Currently, the goals for
neglected tropical disease control and research are shifting
from control to elimination as articulated in the Sustain-
able Development Goal 3 [9]. For schistosomiasis, the
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main control strategy is preventive chemotherapy. How-
ever, for successful elimination, the approach needs to be
strengthened by integrating other control methods such
as early diagnosis and coverage of the whole population in
endemic areas, as well as integrating these efforts with
snail elimination. Global control efforts need to be inclu-
sive of other stakeholders such as primary health centres,
family health clinics and primary school health initiatives,
as well as other sectors such as agriculture, occupations
working in the aquatic environment and, of course, water
and sanitation programmes. Inclusive preventative chemo-
therapy programmes targeting all sectors of the popula-
tion including out-of-reach communities and children out
of school, together with the control of the snail intermedi-
ate host and health education, would have a greater and
longer-lasting impact than chemotherapy alone. This also
means that for elimination to be successful, all animals
and human reservoirs of infection must be targeted for
treatment, which translates into targeting whole popula-
tions in endemic areas.
This review article brings into context the details of
global schistosomiasis control that have been overlooked
during planning for mass treatment, gaps in the current
MDA programmes, the need for a child-size praziquan-
tel tablet, the need for appropriate diagnostics for paedi-
atric schistosomiasis, and the need for complementary
control strategies to curtail recontamination of water
sources and reinfection.
The clinical assessment of infection and morbidity due
to schistosomiasis has mainly been based on haematuria
and the presence of eggs in either urine or stool. De-
tailed confirmation of infection for surveillance pur-
poses, however, has been based on prevalence, infection
intensity, clinical presentations and mortality. Introduc-
tion of mass treatment has resulted in a sharp decrease
of the prevalence as well as the intensity of infection,
and the morbidity of the disease has significantly de-
clined. The clinical presentation of acute schistosomiasis
has not been utilised appropriately for infection diagno-
sis, especially in endemic areas where there are several
other infections with similar clinical presentations.. In
children and infants, the presentations may include
fever, rigor, sweating, headache, general muscular pain,
gastrointestinal disturbances, enlargement and tender-
ness of the liver, and eosinophilia [10]. Heavily infected
patients are usually very sick with a high fever, which
may lead to death. Most subjects with the infection in
endemic areas are chronic cases, with the infection re-
ported to have started during the early years of growth
and exposure to the infective sources. Most children
below the age of five are symptomless, while some are
slightly symptomatic and the impact to their general
growth is usually not significant. While the preschool
age determines the extent of the disease in later age, if
not treated in time, the disease may become advanced
causing higher morbidity. Other patients may have a la-
tent symptomless infection all their life.
Most of the mortality of schistosomiasis is seen in the
advanced stage of the disease. Individuals acquire the in-
fection, usually repeated and heavy, during childhood.
However, after schistosomiasis infection control, there is
usually successful transmission control, yet individuals can
still develop clinical disease. This is likely to occur in
young children and individuals with high water contact
such as women. Therefore, disease control is still needed
in the post-transmission period, in which at-risk popula-
tions are monitored. This is a problem in post-mass treat-
ment for schistosomiasis control in the post-transmission
period and so surveillance and suitable intervention are
needed in areas where transmission is interrupted [10, 11].
In addition, further studies on the pathogenesis of post-
transmission schistosomiasis are necessary.
The data from current efforts in different countries
will require appropriate management in order to moni-
tor the trends of the programmes and evaluate their effi-
cacy. To analyse the efficacy of schistosome control on a
continental scale, a strategy for data collection, manage-
ment and analysis is required. This may also rely on
novel approaches to analyse and interrogate the data, as
has recently been highlighted by Walker and colleagues
[9]. On the laboratory side, field and laboratory diagnos-
tics with higher sensitivity and specificity during surveil-
lances are required, and for eventual success, there is a
need for high uptake of MDA by communities. Current
diagnostics need perfecting to be broadly specific and
highly sensitive for detecting infections, especially after
rounds of preventive chemotherapy treatment efforts
through MDA. After rounds of MDA, many areas would
experience low infection levels, where the point-of-care
circulating cathodic antigen urine cassette test for S.
mansoni diagnosis may be appropriate for use and there
is probably need for improvement of the test for S. hae-
matobium diagnosis in the endemic areas. [12]. In such
low endemic areas, there is a need to establish new cut-
offs/thresholds for diagnosis in regard to low prevalence.
In addition, new diagnostic tools to support control pro-
grammes leading to and evaluating transmission inter-
ruption or even elimination of schistosomiasis need to
be evaluated and scaled up in the form of an up-
converting phosphor technology-based lateral flow anti-
gen assay [11].
Paediatric schistosomiasis: infection and
morbidity
One population exposed to schistosome infection that is
still neglected in terms of schistosome treatment and re-
search is the preschool-age group (five years and below).
Until recently, preschool-aged children were excluded
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from schistosome treatment largely due to a lack of evi-
dence on the need for treatment in this group, as well as
a lack of age-specific safety and efficacy data. Field stud-
ies have shown that young children and infant children
can be passively exposed to schistosome infection, for
example by being bathed in infective water collected
from rivers or playing in infective water while their
mothers or caregivers undertake their domestic water-
related chores at infested water contact points, thus
leading to mothers unknowingly exposing their children
to infections (see Fig. 1). As children grow, their expos-
ure patterns change from passive exposure, predominat-
ing in young infants as their exposure is linked to that of
their careers, to active exposure, as they become more
able to frequent contaminated water sources independ-
ently with older siblings and friends. Studies by others
and us have previously demonstrated that young African
children in several countries including Nigeria, Cote
d’Ivoire, Kenya, Mali, Uganda and Zimbabwe are in-
fected with schistosomes [13–19]. Furthermore, the lim-
ited investigations describing and quantifying morbidity
in this age group have shown that the infections in these
young children are of clinical significance [20–22], indicat-
ing the need to ensure that the preschool-age group is eli-
gible for preventative chemotherapy for schistosomiasis.
Following the recommendations by the WHO in 2010
that this age group requires treatment and the conclusion
following several safety and efficacy studies that prazi-
quantel is both safe and efficacious for use in this age
group, there has been an uptake to include younger chil-
dren in schistosome MDA programmes, albeit slowly. In
studies involving preschool-aged children in sub-Saharan
Africa, including our own in Zimbabwe (for example [11,
16]), the challenge during treatment of infants and youn-
ger children has been the lack of an appropriate child-size
praziquantel tablet. When treating young children with
the currently available commercial praziquantel tablets,
there is a need to break them to get the correct dosage,
followed by crushing them to avoid chocking, and then fi-
nally dissolving or mixing with a sweetener to reduce the
bitter taste. While this may be practical for one or a few
children, the operation becomes cumbersome when deal-
ing with tens or hundreds of young children and infants,
as was the case in our studies, and as would occur to an
even larger extent during MDA.
While it is now acknowledged that preschool-aged
children are exposed to infection and do get infected
with schistosomes, there is still some distance to go in
order to define and fully quantify the health impacts at-
tributable to schistosomiasis in this age group. There is
a need for more sensitive diagnostics, such as serology,
faecal occult blood or micro haematuria to reveal early-
stage infections, thereby providing disease diagnostics
and treatment before early signs of serious morbidity
and pathology. Some reports on S. mansoni infections
using ultrasonography have highlighted that advanced
disease such as chronic fibrosis can be traced back to
preschool-age childhood [10, 23].
Paediatric disease case management for clinical schis-
tosomiasis is rare in most endemic areas, since the dis-
ease is poorly recognised and rarely considered in
younger children before the school-going age. Very few
Fig. 1 While the mother is busy with laundry chores, the child is placed in a dish with water collected from the river, exposing the child to
infection if the water contains cercariae. This was observed to be a common practice in the community where children aged below five years
were found to harbour the S. haematobium infection
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health personnel in rural settings understand the range
of schistosomiasis clinical manifestations related to early
child health. More detailed studies of exposure patterns
are required in this age group to quantify the relative
contributions of passive versus active exposure [24–26],
as well as to understand the course of pathology during
the early stages of infection and child development. The
health impact of paediatric schistosomiasis is likely to be
greater than currently appreciated. Several studies have
demonstrated that children experience the greatest mor-
bidity due to schistosomiasis that manifests in fever and
inflammation, which leads to poor health and food in-
take, resulting in undernutrition, in these settings [27].
Early care for and attention to this age group may pro-
vide an opportunity to treat schistosomiasis-associated
anaemia, reduce occult blood loss and also reduce in-
flammatory responses [28]. Schistosome-related inflam-
mation may predispose to poor child growth, as well as
decreased efficacy of childhood vaccines [12, 28]. Thus,
treatment of schistosomiasis has the dual benefit of
treating inflammation due to infection and maximising
the efficacy of childhood vaccinations. Early treatment of
children in Schistosoma-endemic regions may therefore
enhance downstream benefits of vaccine programmes,
improve educational attainment and cognitive ability, as
well as improve overall health outcomes [21, 25].
Praziquantel target product profile and accessing
preschool-aged children for treatment
As outlined earlier, the current existing praziquantel tablet
has to be broken into small pieces and sometimes crushed
for the under-five-year-old child to take. Studies by others
and us have described the limitations of the current tablet
formulation for the treatment of preschool-aged children
[22, 25, 28], which include tablet size, tablet dose and poor
palatability [24–26]. There is a need to improve on the
currently available tablet. In addition to being efficacious,
a clear target product profile for paediatric praziquantel
has been deduced from our studies, which includes, but is
not limited to, the following:
1. safe and well tolerated with little to no side effects;
2. small and easy to swallow to avoid chocking;
3. orally disintegrated and can be taken with or
without water (in cases of unsafe water supply);
4. improved taste for minimisation of bitterness, easy
dose adjustment by number of tablets to avoid
having to break tablets; and
5. stability in hot and humid conditions.
To reach all eligible children, the paediatric formula-
tion must also be affordable, preferably costing no more
that the current praziquantel tablet, priced at US$ 0.30
per tablet as in most sub-Saharan region.. On the
research side, there is a need to optimise treatment by
determining the most efficacious dose, as well as the
most optimal treatment time and regimen (e.g. fre-
quency of treatment), for these young children. Once we
have a paediatric formulation of praziquantel satisfying
these requirements, the next aspect of treating younger
children is dependent on how to access them.
Primary school children are easily reacheable for hel-
minth control programmes through nearby schools and
health centres. There has been discussion [26, 28] on how
to best access preschool-aged children, some of whom
may not yet be enrolled in Early Childhood Development
centres. In sub-Saharan Africa, the Expanded Programme
on Immunization for children below five years of age has
shown that this age group is easily accessible through the
primary health monthly child care programmes, and in
our studies in Zimbabwe we access these children through
the primary healthcare system [16, 28]. In other countries,
Child Health Days also offer a potential opportunity for
easily reaching these age groups.
Praziquantel pharmacokinetics in preschool-aged
children
Recent praziquantel pharmacokinetic and pharmaco-
dynamics studies suggest that the efficacy of the current
40 mg/kg body weight, which is extrapolated from stud-
ies in adults, may differ for different schistosome species
and may also differ for children [21]. For example, prazi-
quantel is currently given at a dose of 40 mg/kg body
weight in Africa [19], and 50 mg/kg for adults and
60 mg/kg for children in South America [21]. The calcu-
lation of the dose based on weight and the variability of
praziquantel absorption relative to food and drink taken
simultaneously leads to differences in the pharmacokin-
etics of praziquantel in children and adults [21, 22, 29,
30]. The relative impact of this on efficacy and safety of
any new formulations will therefore need to be investi-
gated. There will be a need for studies investigating the
optimal dose for any paediatric formulation of prazi-
quantel, especially if the formulation excludes the in-
active isomer responsible for the bitter taste of the
currently available praziquantel tablets. Removal of the
non-active ingredients may affect the stability of the new
formulation, affecting the pharmacokinetics of the drug
and the eventual levels and half-life of the bioactive drug
in circulation. The recent development of the child-size
praziquantel through the Paediatric Praziquantel Con-
sortium is encouraging. Post-human trials assessment of
the new formulation for different Schistosoma species
and using well-designed studies across the affected areas
to cater for differences in human host genetics will be
important. The evaluation trials of a new paediatric for-
mulation should target the different endemic countries
with different species and also different age groups. As
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the patent is no longer restrictive, more formulations
and trials of praziquantel tablets should be supported to
encourage local formulations to be developed in en-
demic countries. Lessons can be learnt from the experi-
ences of South Africa as they forge ahead to produce
anti-retroviral drugs locally in 2017 [31].
Knowledge gap in paediatric praziquantel
pharmacogenomics
Pharmacogenomics and pharmacogenetics help us
understand the genetics associated with poor response
(i.e. the lack of therapeutic response and resistance to
treatment of infectious agents) and poor tolerance
(including development of adverse drug reactions,
ADRs) to drugs in a healthcare setting. Identification
of predictors of drug discontinuation remains a major
priority in a healthcare setting [32]. Pharmacogenom-
ics has become an important field of science due to
the potential to develop personalised medicine. This
is relevant in developing countries where most ex-
pertise that is needed to deal with the effects of
ADRs are not available, as medical prescription prac-
tices are based on the theory of one-size-fits-all.
Development of a child-size praziquantel tablet pro-
vides an opportunity to investigate genetic impacts on
praziquantel pharmacokinetics. In general, there is a
growing appreciation that genomic variants can be used
to successfully predict individual responses to drug ther-
apy in terms of efficacy and toxicity. The mechanisms
revolve around genes responsible for drug metabolism,
drug transport and drug targets (i.e. receptors).
Genome-wide association studies and whole genome se-
quencing technologies are likely to identify gene variants
that have not previously been considered to play a role
in either the disposition or mode of action of a drug,
thus these technologies can be used as major resources
for novel insights into pathways involved in drug re-
sponse [31–34]. Very little pharmacokinetics work has
been conducted in African populations [35–37]. In this
respect, many serious ADRs are only discovered post-
licensure of the medications in advanced phases of clin-
ical trials [38, 39].
Conclusion
The inclusion of preschool-aged children in MDA pro-
grammes is essential for the successful and sustained
control of schistosomiasis and critical for eventual elim-
ination. It is encouraging that the global community, in-
cluding the Global Schistosomiasis Alliance and the
Paediatric Praziquantel Consortium, are working on pro-
viding the tools to facilitate this, the most urgent being a
paediatric formulation of praziquantel.
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